ID Signaling Pathway in Oncology Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||171750|
Inhibitor of DNA binding (ID) proteins are members of the helix-loop-helix (HLH) family of proteins which lack a DNA binding domain themselves but bind to other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4.
There are today 117 companies plus partners developing 114 ID pathway targeting drugs in 493 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 62 drugs. Id Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 104 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 104 out of the 104 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 25 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator